Treatment switch guided by HIV-1 genotyping in Brazil

Brazilian Journal of Infectious Diseases

Volumn 10, Issue 2, 2006, Pages 82-88

  Tupinambás, Unaí ^a,b,c   Ribeiro, Flávia Andrade ^a   Aleixo, Agdemir ^a   Greco, Dirceu ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Secretary of Health   (Brazil)

^c NONE   (Brazil)

Author keywords

Antiretroviral resistance testing; Genotyping; HIV 1

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NONHUMAN; OPEN STUDY; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PHARMACY; TREATMENT DURATION; VIRUS LOAD;

EID: 33746863736     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702006000200003     Document Type: Article

References (18)

1. Marins J.R., Jamal L.F., Chen S.Y., et al. Dramatic improvement in survival among adult Brazilian Aids patients. AIDS 2003;17:1675-82.
2. Hoetelmans Richard. Pharmacological exposure and development of drug resistance in HIV. Antiviral Therapy 2001;6(Suppl.2):37-47.
3. Wit F.W., van Leewen R., et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency type-1 infected persons. Journal of Infectious Diseases 1999;179:790-8.
4. Erice A., Mayers D., Strike D., et al. Primary Infection with Zidovudine-Resistant Human Immunodeficiency Virus Type 1. N Eng J Med 1993;328:1163-5.
5. Durant J., Clevenbergh P., Halfon P., et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. The Lancet 1999;353:2195-9.
6. Baxter J.D., Mayers D.L., Wentworth D.N., et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000;14:F83-F93.
7. Meynard J.L., Vray M., Morand-Joubert L., et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002;16:727-36.
8. Cingolani A., Antinori A., Rizzo M.G., et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002;16:369-79.
9. Tural C., Ruiz L., Holtzer C., et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002;16:209-18.
10. Chaix C., Grenier-Sennelier C., Clevenbergh P., et al. Economic evaluation of drug resistence genotyping for the adaptation of treatment in HIV infected patients in the VIRADAPT study. J Acquir Imm Defic Synd 2000;24;227-31.
11. Shafer R.W., Hertogs K., Zolopa A.R., et al. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol 2001;39:1529-52.
12. Dáquila R.T., Schapiro J.M., Brun-Vezinte F., et al. Drug resistance mutations in HIV-1. Top HIV Med 2003;11:92-96
13. Pereira MG. Epidemiologia - Teoria e Prática. Rio de Janeiro: Editora Guanabara Koogan S.A.,583p.,1995.
14. Durant J., Clevengberth P., Garraffo R., et al. Importance of protease inhibitor plasma levels in HIV infected patients treated with genotyping-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000;14:1333-9.
15. Lignani J.R. Avaliação da aderência aos anti-retrovirais em amostra de pacientes acompanhados no Centro de Treinamento e Referência em Doenças Infecciosas e Parasitárias, Belo Horizonte-MG. Dissertação de Mestrado, 103 p., 2000.
16. Haubrich R.H., Little S.J., Currier J.S., et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999;13:S189-S204.
17. Hecht F.M., Colfax G., Swanson M., et al. Adherence and effectiveness of protease inhibitors in clinical practice. In: Fifth Conference on retrovirus and Opportunistic Infections. Chicago, February 1998. {Abstract 151}.
18. Hirsch M.S., Brun-Vézint F., Clotet B., et al. Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society-USA Panel. CID 37:113-28.